This Article Full Text Full Text (PDF) All Versions of this Article: 37/6/1572    most recent 01.STR.0000221298.43117.bev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chaturvedi, S. Articles by Yadav, J. S. Search for Related Content PubMed PubMed Citation Articles by Chaturvedi, S. Articles by Yadav, J. S. Pubmed/NCBI databases Medline Plus Health Information Blood Thinners Stroke Related Collections Pathophysiology Carotid Stenosis Antiplatelets Angioplasty and Stenting Platelets

(Stroke. 2006;37:1572.)
© 2006 American Heart Association, Inc.

Comments, Opinions, and Reviews

The Role of Antiplatelet Therapy in Carotid Stenting for Ischemic Stroke Prevention

From the Comprehensive Stroke Program and Department of Neurology (S.C.), Wayne State University, Detroit, Mich; and the Department of Cardiovascular Medicine (J.Y.), Cleveland Clinic Foundation, Ohio.

Correspondence to Seemant Chaturvedi, MD, Department of Neurology, Wayne State University, 8C–UHC, 4201 St Antoine Blvd, Detroit, MI 48201. E-mail schaturv{at}med.wayne.edu

Background and Purpose— Carotid angioplasty and stenting (CAS) is a minimally invasive revascularization procedure that has become a popular and acceptable treatment option in the United States for high surgical risk patients with internal carotid artery atherosclerosis. It is effective and has an acceptable risk profile, but ischemic complications caused by distal embolization and underlying atherothrombosis persist.

Summary of Review— Atherothrombosis is the pathological process that is frequently implicated as the underlying cause of stroke, transient ischemic attacks, and most other ischemic vascular disease. Critical steps in the development of occlusive episodes are the disruption of atherosclerotic plaque and subsequent formation of a platelet-rich mural thrombus. Vascular injury as a result of CAS or any other percutaneous intervention triggers platelet adhesion, activation, and aggregation, resulting in the formation of a mural thrombosis. This risk, in addition to the potential risk of embolization to distal sites, provides a rationale for early antiplatelet therapy with CAS. The risk of late stent (>30 days after stenting) thrombosis in some patients, particularly those receiving drug-eluting stents, provides a rationale for prolonged antiplatelet prophylaxis as well as for prophylaxis against late atherothrombotic events. Because of the systemic and progressive nature of atherothrombosis, protection against ischemic vascular events in other arterial beds expands the benefits of long-term antiplatelet therapy.

Conclusions— As clinical experience with CAS increases, it is likely that it will be used more frequently for patients with occlusive carotid disease. In addition, adjunct antiplatelet therapy will play a key role in the continued development of CAS.

Key Words: antiplatelets • carotid angioplasty • carotid artery stenosis • stents

This article has been cited by other articles:

				F. Liu, J. Li, D.-M. Wang, J.-C. Liu, and Y.-N. Huang Serial Changes of Circulating Platelet Activation Markers After Carotid Artery Stenting Angiology, August 1, 2009; 60(4): 427 - 430. [Abstract] [PDF]

				R. F. Bonvini, M. Righini, M. Hamon, J. W. Riddell, A. O. Maree, K. A. Rosenfield, J.-L. Mas, G. Chatellier, and the EVA-3S Investigators Endarterectomy versus Stenting for Carotid Stenosis N. Engl. J. Med., January 18, 2007; 356(3): 305 - 307. [Full Text] [PDF]

				J. Kramer, J. Abraham, C. M. Teven, and P. A. Jones Role of Antiplatelets in Carotid Artery Stenting Stroke, January 1, 2007; 38(1): 14 - 14. [Full Text] [PDF]